Johnson & Johnson (NYSE: JNJ) is recommended as one of the best medical stocks to buy now by Barclays analyst Matt Miksic, who maintained a Hold rating and set a price target of $176.00. The company recently received approval for its TREMFYA treatment for pediatric patients with plaque psoriasis and psoriatic arthritis, based on the positive results of the PROTOSTAR study. Johnson & Johnson operates in the healthcare field through two segments: Innovative Medicine and MedTech, offering a wide range of medical devices and products. Despite its potential, some believe other AI stocks may offer greater upside potential.

Read more at Yahoo Finance: Barclays Maintains a Hold Rating on Johnson & Johnson (JNJ) With a $176 PT